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Abstract
Background:  Angiotensin converting enzyme inhibitors (ACE inhibitors) reduce peripheral
vascular resistance via blockage of angiotensin converting enzyme (ACE). ACE inhibitors are
commonly used to treat congestive heart failure and high blood pressure, but other effects have
been reported. In this study, we explored the association between ACE inhibitor therapy and the
prevalence of comorbid conditions in adults with diabetes
Methods: We surveyed 1003 adults with diabetes randomly selected from community practices.
Patients were interviewed at home and self-reported their personal and clinical characteristics
including comorbidity. Current medications were obtained by direct observation of medication
containers. We built logistic regression models with the history of comorbidities as the outcome
variable and the current use of ACE inhibitors as the primary predictor variable. We adjusted for
possible confounding by social (age, sex, alcohol drinking, cigarette smoking) and clinical factors
(systolic blood pressure, body mass index (BMI), glycosolated hemoglobin (A1C), number of
comorbid conditions, and number of prescription medications).
Results: ACE users reported a history of any cancer (except the non-life-threatening skin cancers)
less frequently than non-users (10% vs. 15%; odd ratio = 0.59; 95% confidence interval [0.39, 0.89];
P = 0.01); and a history of stomach ulcers or peptic ulcer disease less frequently than non-users
(12% vs. 16%, odd ratio = 0.70, [0.49, 1.01], P = 0.06). After correcting for potential confounders,
ACE inhibitors remained significantly inversely associated with a personal history of cancer (odds
ratio = 0.59, [0.39, 0.89]; P = 0.01) and peptic ulcer disease (odd ratio = 0.68, [0.46, 1.00], P = 0.05).
Conclusion: ACE inhibitor use is associated with a lower likelihood of a history of cancer and
peptic ulcers in patients with diabetes. These findings are limited by the cross sectional study
design, self-report of comorbid diagnoses, and lack of information on the timing and duration of
ACE inhibitor use. Further research is needed to confirm these associations and understand their
mechanisms.
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Background
Although introduced for the treatment of hypertension,
angiotensin converting enzyme (ACE) inhibitors are also
able to reduce morbidity and mortality in congestive heart
failure and post myocardial infarction, and to prevent re-
infarction (reviewed in [1]), but have been found to have
other benefits. For example, ACE inhibitors have been
observed to slow the progression of diabetic nephropathy
[2,3]. Lever et al. [4] found that users of ACE inhibitors
exhibited a reduced risk of cancer (RR = 0.63; 95% CI,
0.41–0.93). Koh et al. [5] found that individuals possess-
ing low-activity ACE alleles were at a reduced risk of breast
cancer, suggesting that inhibition of the angiotensin II
effect by blockade of ACE could be potential targets for
the prevention and treatment of breast cancer.
Diabetes increases the risk of vascular complications [6].
Evidence from large-scale clinical trials has suggested that
attenuation of the renin-angiotensin-aldosterone system
by ACE inhibitors may reduce cardiovascular morbidity
and mortality in diabetic patients with established cardio-
vascular disease [7-9]. ACE inhibitors may also increase
survival in diabetes patients without heart disease and
some large studies have shown that ACE inhibitors were
able to reduce the risk of developing diabetes itself [10].
Here, we report the association between ACE inhibitor
therapies and cancer or stomach/peptic ulcer disease in
diabetic patients.
Methods
This study is part of a larger project, the Vermont Diabetes
Information System (VDIS), a study of 8,855 adults with
diabetes in primary care practices [11]. The subjects com-
prised all diabetic adults in 69 practices in Vermont and
adjacent New Hampshire and New York. A field survey
was completed at study baseline in a sub-sample of sub-
jects. Patients' names were randomly sorted and patients
contacted by telephone until approximately 15% of
patients from each practice agreed to participate in the
field survey. Four patients were dropped from the analysis
due to incomplete information leaving a final sample of
1,003.
Subjects completed a questionnaire at home and were vis-
ited by a trained research assistant who reviewed the ques-
tionnaire responses, assisted the subject with any missing
or unacceptable responses, reviewed the subject's medica-
tions, and measured their blood pressure, height and
weight using a portable sphygmomanometer, stadiome-
ter, and scale. Race, education, income, marital status,
functional status, smoking, alcohol consumption, and
comorbid conditions were obtained by questionnaire.
Prior to the interview, patients were instructed to gather
all current medications, including over the counter prepa-
rations, for review by the research assistant. The medica-
tion list was ascertained by direct observation of the
medication container with recording of the drug name,
dose, frequency, and route of administration. Duration of
therapy was not recorded.
To determine comorbidity, we used a modification of the
Self-Administered Comorbidity Questionnaire [12] in
which we asked each patient to indicate whether they
have had the following conditions: coronary artery dis-
ease (CAD), congestive heart failure (CHF), peripheral
vascular disease (PVD), cerebrovascular accident or stroke
(CVA), Alzheimer or any other dementia, asthma/chronic
obstructive lung disease, rheumatic disease (rheumatoid
arthritis, lupus or polymyalgia rheumatica), stomach
ulcers or peptic ulcer disease (PUD), cirrhosis, paralysis,
renal insufficiency, microvascular complications (eye,
nerve, kidney damage related to diabetes), AIDS/HIV, and
depression. All patients had diabetes which was not
included in the comorbidity count. Patients were classi-
fied as having cancer if they reported any non-skin cancer
including leukemia or lymphoma. Specific cancer sites
and dates of diagnosis were not recorded.
The interviews occurred between July 2003 and March
2005. Most laboratory data were obtained from the
Table 1: Baseline characteristics of 1,004 adults with diabetes.
Characteristic n (%) or mean (sd)
Ace Inhibitors use 445 (44.3%)
Men 457 (45.5%)
Age, years 64.8 (12.0)
Systolic Blood Pressure, mmHg 140.3 (19.6)
Glycosolated hemoglobin A1C, % 7.12 (1.3)
Body mass index, kg/m2 33.81 (7.4)
Alcohol use 274 (27.4%)
Cigarette smoking 170 (17.0%)
Number of comorbid conditions 1.8 (1.7)
Number of prescription medications 6.7 (3.8)
Rheumatic disease 142 (14.2%)
Asthma/chronic obstructive lung disease 203 (20.2%)
Coronary artery disease 193 (19.2%)
Cancer 126 (12.6%)
Congestive heart failure 172 (17.2%)
Cirrhosis 18 (1.8%)
Stroke 118 (11.8%)
Depression 351 (35.0%)
Foot ulcers 111 (11.2%)
Foot/leg pain 291 (31.0%)
Microvascular disease 170 (17.0%)
Paresis 30 (3.0%)
Peptic ulcer disease 143 (14.3%)
Peripheral vascular disease 88 (8.8%)
Renal problems 50 (5.0%)
Sexual dysfunction 244 (26.6%)
Stomach emptying 56 (6.2%)
sd = standard deviation; n = number of subjects with the 
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patients' local clinical laboratories, which all use the same
Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications high per-
formance, liquid chromatography (HPLC) method for the
determination of glycosylated hemoglobin (A1C). Less
than 1% of A1C tests were done using the Bayer DCA
2000 immunoassay point of care instrument, which has
been shown to compare favorably with the HPLC method
[13].
The research protocol was carried out in compliance with
the Helsinki Declaration and was approved by the Com-
mittee on Human Research of the University of Vermont.
The interviewed subjects provided written informed con-
sent. The full study protocol and variables, and the medi-
cation profiles of the subjects have been previously
reported [11,14].
We performed a cross sectional analysis of the interviewed
subjects at the time of their enrollment in the VDIS trial.
We explored the association between rheumatic disease,
asthma/COPD, CAD, cancer, CHF, cirrhosis, CVA, depres-
sion, paresis, PUD, PVD, and the use of ACE inhibitors
therapy using logistic regression with each condition as
the outcome variable and the use of ACE inhibitors as the
primary predictor variable. We then adjusted for possible
confounding by social and clinical factors including gen-
der, age (years), systolic blood pressure (mmHg), glyco-
sylated hemoglobin level (A1C in mg%), body mass index
(BMI in kg/m2), current alcohol use (yes/no), current cig-
arette use (yes/no), number of comorbidities, and
number of prescription medications. The selection of
these potential confounding conditions was based on
clinical and epidemiologic judgment and not on statisti-
cal determinants. We used Stata/SE 9.2 (StataCorp, Col-
lege Station, TX) for all analyses.
Results
The study population was representative of adults with
diabetes in primary care practices in Northern New Eng-
land. See Table 1.
Table 2 presents the univariate associations between each
comorbid condition and the use of ACE inhibitors. Can-
Table 3: Univariate associations between ACE inhibitor therapy and other patient characteristics.
Characteristic ACE inhibitor users
% or mean (sd)
ACE inhibitor users
% or mean (sd)
Odds Ratio P
Number of subjects 558 445
Age, years 65.2 (12.1) 64.3 (11.9) 0.99 0.24
Men 41.5% 50.6% 1.44 0.004
Systolic Blood Pressure 139.7 (18.8) 141.0 (20.5) 1.00 0.28
Glycosolated 7.1 (1.3) 7.2 (1.3) 1.10 0.05
hemoglobin A1C, %
Body mass index, kg/m2 33.2 (7.3) 34.6 (7.4) 1.03 0.002
Alcohol drinking 30.2% 23.8% 0.72 0.03
Cigarette smoking 18.5% 15.1% 0.78 0.15
Comorbidity conditions 1.81 (0.1) 1.83 (0.1) 1.01 0.82
Number of prescription meds 6.2 (3.9) 7.2 (3.5) 1.10 <0.0001
Table 2: Univariate associations between comorbidity and ACE inhibitor therapy.
Comorbidity ACE inhibitor non- users
n (%)
ACE inhibitor users
n (%)
Odds Ratio P
Rheumatic disease 80 (14.3) 62 (13.9) 0.97 0.86
Asthma/COPD 116 (20.8) 87 (19.6) 0.93 0.63
CAD 98 (17.6) 95 (21.4) 1.27 0.13
Cancer 82 (14.7) 44 (9.9) 0.64 0.02
CHF 87 (15.6) 85 (19.1) 1.28 0.14
Cirrhosis 9 (1.6) 9 (2.0) 1.26 0.63
CVA 70 (12.5) 48 (10.8) 0.84 0.39
Depression 198 (35.5) 153 (34.4) 0.95 0.72
Paresis 17 (3.1) 13 (2.9) 0.96 0.91
PUD 90 (16.1) 53 (11.9) 0.70 0.06
PVD 45 (8.1) 43 (9.7) 1.22 0.38
N = 1003BMC Endocrine Disorders 2008, 8:17 http://www.biomedcentral.com/1472-6823/8/17
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cer and PUD were significantly associated with ACE inhib-
itors therapy. Table 3 presents the univariate association
between ace inhibitor therapy and other patient character-
istics. Ace inhibitor use is significantly associated with
being male, having higher glycosylated hemoglobin level
(A1C), having higher body mass index (BMI, kg/m2), hav-
ing higher number of prescription medications, and being
a non-drinker.
Univariate associations between potential confounding
variables and cancer were evaluated (Table 4) and a logis-
tic regression model constructed using cancer as the out-
come and all potential confounders: gender, age (years),
systolic blood pressure (mmHg), glycosylated hemo-
globin level (A1C) (mg%), body mass index (BMI, kg/
m2), alcohol drinking (yes/no), cigarette smoking (yes/
no), number of comorbidities, and number of prescrip-
tion medications. This model showed a significant associ-
ation between cancer and the use of ACE inhibitors (OR =
0.59, 95%CI [0.39, 0.89], P = 0.01) (Table 5). Other vari-
ables significantly associated with cancer history included
age and number of prescription medications (Table 5).
Similarly, Table 6 presents the univariate associations
between PUD and potential confounding variables. The
logistic regression model showed a significant negative
association with ACE inhibitors use (OR = 0.68, 95%CI
[0.46, 1.00],P = 0.05) (Table 7). Other variables signifi-
cantly associated with PUD history included alcohol
drinking and comorbid conditions.
Discussion
These data suggest a negative association of ACE inhibitor
use with both cancer and PUD in a community based
population of adults with diabetes.
Evidence from animal models suggests that angiotensin II
stimulates neovascularization [17] and promote angio-
genesis in neoplastic growth. Angiotensin II may also act
as a mitotic factor by inducing or regulating gene expres-
sion in cell cycle progression [18]. The ACE inhibitor cap-
topril has been shown to inhibit proliferation of a variety
of cell types, including human breast cancer [16,19,20],
and to reduce tumor growth in experimental models of
cancer [21,22]. Some epidemiological evidence also sug-
gests protective effects of ACE inhibitors on cancer [4,5].
Here we present additional evidence of a potential nega-
tive association between cancer and the use of ACE inhib-
itors in a diabetic population.
Very few reports have looked at the association between
ACE inhibitors and peptic ulcers. One study found that
captopril significantly reduced the development of gastric
ulcers in pylorus-ligated rats [23]. Another found that cap-
topril and naloxone significantly reduced ulcer formation
induced by stress in rats [24]. Mou et al. [25] determined
that endogenous angiotensin II plays a role in the devel-
opment of stress ulcers in rats with obstructive jaundice
and that ACE inhibitors prevented their development. A
report by Iakubov and Usmanova [26] indicated that pro-
phylactic use of ACE inhibitors reduced indomethacin-
induced ulcers and erosions of the stomach in humans.
They suggested that the reparative functions of the
Table 5: Multivariate associations between cancer and other 
patient characteristics
Characteristic Odds Ratio P
ACE inhibitor therapy 0.59 0.01
Age, years 1.02 0.02
Male 0.88 0.56
Systolic Blood Pressure, mmHg 1.01 0.28
Glycosolated hemoglobin A1C, % 0.95 0.52
Body mass index, kg/m2 0.98 0.15
Alcohol drinking 1.07 0.77
Cigarette smoking 0.68 0.22
Number of comorbid conditions 0.97 0.61
Number of prescription medications 1.09 0.01
N = 974
Table 4: Univariate associations between cancer and other patient characteristics.
Characteristic Cancer Patients
% or mean (sd)
Non-Cancer Patients
% or mean (sd)
Odds Ratio P
Number of subjects 126 877
ACE inhibitor therapy 34.9% 45.7% 0.64 0.02
Age, years 69.1 (10.2) 64.2 (12.1) 1.04 <0.001
Male 42.1% 46.1% 0.85 0.40
Systolic Blood Pressure, mmHg 143.0 (20.9) 139.9(19.4) 1.01 0.10
Body mass index, kg/m2 32.6 (6.8) 34.0 (7.5) 0.97 0.06
Alcohol drinking 25.4% 27.6% 0.89 0.60
Cigarette smoking 11.1% 17.8% 0.58 0.06
Number of comorbid conditions 1.8 (2.0) 1.7 (1.6) 1.05 0.41
Number of prescription medications 7.3 (4.3) 6.6 (3.7) 1.05 0.05BMC Endocrine Disorders 2008, 8:17 http://www.biomedcentral.com/1472-6823/8/17
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mucous of the gastrointestinal track were influenced by a
reduction of angiotensin II formation and activation of
the renin-kallicrein-kinin system. These animal studies
support the findings that ACE inhibitors may protect
against PUD. We are aware of no prior studies of the asso-
ciation between ACE inhibitors and PUD in humans, but
Sugimoto et al. [27] suggested that ACE gene polymor-
phisms were associated with cancer risk and gastric ulcers
in Japan.
The mechanisms of the observed associations between
ACE inhibition and the two diagnoses are unknown. It is
possible that ACE inhibitors protect against the develop-
ment of cancer or ulcer disease, although confirmation of
these hypotheses must await additional investigation.
Another interpretation of our results is the "treatment-risk
paradox" in which the history of cancer or ulcer disease
inhibits the use of ACE inhibitors, perhaps due to con-
cerns of polypharmacy or intolerance of the medication
due to the underlying disease. However, the prescribing
information for ACE inhibitors does not discourage their
use in either cancer or PUD and univariate analysis shows
no significant differences between the number of comor-
bidities in ACE inhibitor users and non-users. These facts
argue against the "treatment-risk paradox" theory,
although not conclusively.
This study has several strengths. First, the interviewed sub-
jects were a randomly selected subset of a large population
of patients receiving care in the Northeast, and are there-
fore likely to be representative of primary care patients
generally. Second, all data on medications were obtained
by direct observation in the patient's home and not from
secondary sources. Third, multiple potential confounders
were assessed and found to have no significant effect on
the apparent associations between ACE inhibition and
PUD and cancer.
This study has several limitations including lack of clinical
confirmation of the comorbid diagnoses, and lack of
information on the timing and duration of ACE inhibitor
treatment relative to the onset of the comorbidities. As in
any cross-sectional study, unmeasured confounders may
be responsible for the apparent associations found.
Conclusion
These data suggest a potential protective association of
ACE inhibitors for cancer and peptic ulcer disease in
patients with diabetes. Further research is needed to con-
firm these associations and understand their mechanisms.
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Table 7: Multivariate associations between PUD and other 
patient characteristics
Characteristic Odds Ratio P
ACE inhibitor therapy 0.68 0.05
Age, years 1.00 0.96
Male 1.15 0.49
Systolic Blood Pressure, mmHg 0.99 0.23
Glycosolated hemoglobin A1C, % 0.94 0.40
Body mass index, kg/m2 1.01 0.57
Alcohol drinking 0.47 0.005
Cigarette smoking 1.51 0.09
Number of comorbid conditions 1.32 <0.001
Number of prescription medications 1.01 0.68
N = 974
Table 6: Univariate associations between PUD and other patient characteristics.
Characteristic PUD Patients
% or mean (sd)
Non-PUD Patients
% or mean (sd)
Odds Ratio P
Number of subjects 143 860
ACE inhibitor therapy 37.1% 45.6% 0.70 0.06
Age, years 65.0 (11.8) 64.8 (12.0) 1.00 0.83
Male 43.4% 45.9% 0.90 0.57
Systolic Blood Pressure, mmHg 137.7 (19.5) 140.7(19.6) 1.00 0.09
Glycosolated hemoglobin A1C, % 7.1 (1.3) 7.1 (1.3) 1.00 0.71
Body mass index, kg/m2 34.6 (7.4) 33.7 (7.4) 1.01 0.16
Alcohol drinking 14.7% 29.5% 0.41 <0.001
Cigarette smoking 24.5% 15.7% 1.74 0.01
Number of comorbid conditions 2.5 (1.8) 1.5 (1.5) 1.4 <0.001
Number of prescription medications 8.0 (4.2) 6.4 (3.7) 1.11 <0.001Publish with BioMed Central    and   every 
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